This webinar is the second in a two-part series that looks at racial equity in the drug development system, from investment all the way through access. This forum will focus on equity in the patent system, clinical trials, healthcare delivery, and affordability.
Kaiser Permanente’s Institute for Health Policy invites you to join a two-part virtual forum examining racial equity in the drug development system, from research all the way through to access. This first conversation on December 7 will specifically explore racial inequities in drug investment and research and identify new directions for the future.
This event brought together school and early childhood professionals to discuss how to mitigate and address trauma across children’s lifespans.
Kaiser Permanente's Institute for Health Policy, in collaboration with the National Center for School Mental Health Annual Conference, will bring together leaders from across sectors in Austin in November to discuss the current state of adverse childhood experiences research, evidence-based programs, and funding strategies at the state and federal level.
This event brought together leaders from across sectors to advance the conversation on defining and assessing drug value and elevate policy opportunities that encourage a value-based approach to drug pricing.
On May 2, 2019, the Kaiser Permanente Institute for Health Policy hosted a forum, Taking Action to Prevent Suicide, at Kaiser Permanente’s Center for Total Health in Washington, D.C.
One in 5 Americans have a mental heal condition, but more than half don’t receive treatment. This event brought together leaders from across sectors to discuss challenges facing the mental health workforce and elevate effective solutions.
Nearly half of U.S. children have had at least one adverse childhood experience (or ACE), which can have lasting impacts on their physical and mental health even into adulthood. This event brought together leaders from across sectors to discuss innovative ways to prevent and address trauma in children in school, community, and clinical settings.
Drug companies continue to raise prices to unaffordable levels, making it difficult for patients to access the medication they need to be healthy. This event brought together leaders from across sectors to discuss the drug pricing landscape and elevate effective policy solutions.